WuXi XDC Achieves GMP Release for Singapore BCM3 Facility

WuXi XDC Cayman Inc. has achieved Good Manufacturing Practice (GMP) release for its new BCM3 dual-function production line at its Singapore site. This marks a significant expansion of the company's capabilities to support global clients in the development and manufacturing of bioconjugates.

The BCM3 line is designed for dual functionality and is integrated into WuXi XDC's Singapore facility. It is expected to enhance the company's production capacity and flexibility to meet the growing demand for bioconjugate drugs. Bioconjugates are complex biological medicines that combine monoclonal antibodies with small-molecule drugs.

The company, listed on the Hong Kong Stock Exchange under the stock code 2268.HK, operates as a Contract Research, Development, and Manufacturing Organization (CRDMO) for the bioconjugate industry. The implementation of this new facility strengthens its position in the sector and its commitment to delivering high-quality services to its clients worldwide.

WuXi XDC's Singapore facility is a key component of its global manufacturing network. The GMP release for the BCM3 line enables the company to produce high-quality and compliant bioconjugates to meet client requirements.